Latest Breaking News On - Ongoing research may lead - Page 1 : comparemela.com

Findings of MANIFEST-2 show “valuable evidence that the addition of pelabresib offers meaningful improvements over JAK inhibitor monotherapy as a first-line approach for patients with myelofibrosis,” according to one expert.

North carolinaUnited statesNew yorkWinston salemSan diegoJohn mascarenhasRubena mesaTisch cancer institute at mount sinaiDrug administrationAtrium health levine cancer centerAmerican society for hematologyTisch cancer instituteMount sinaiOngoing research may leadExciting advancementsMyelofibrosis years down